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Background: PROSPECT demonstrated that in patients with acute coronary syndromes (ACS) who undergo percutaneous intervention, the presence 
of untreated non-culprit lesions (NCLs) with plaque burden ≥70%, minimal luminal area ≤4.0 mm2, and/or thin-cap fibroatheromas (TCFA) is 
associated with subsequent major adverse cardiovascular events (MACE). C-reactive protein (CRP) has been proposed as a marker of vulnerable 
plaque and adverse events, but these relationships have not been studied in vivo.
Methods: MACE was defined as cardiac death, cardiac arrest, myocardial infarction, or rehospitalization for progressive/unstable angina. CRP 
was measured at baseline and at 30 and 180 days. Events prior to these points were excluded. CRP values were stratified as normal ( < 3 mg/L), 
abnormal (3-10 mg/L), or high risk ( > 10 mg/L).
Results: CRP levels at baseline and 30d had no relationship with late NCL-related MACE. Elevated CRP levels at 180d were associated with late 
NCL-MACE but were not associated with differences in median plaque burden, median MLA, or the presence of TCFAs (table).
Conclusion: In patients with ACS who underwent percutaneous intervention, CRP levels at baseline and 30d did not predict late NCL-MACE. CRP 
levels at 180d predicted late NCL-MACE but were not related to high-risk plaque characteristics identified by gray-scale and radiofrequency IVUS. 
Normal
(<3 mg/L)
Abnormal
(3-10 mg/L)
High Risk
(>10 mg/L)
P-value
N=366 N=90 N=31
Median plaque burden, % 49.4 [46.7,52.1] 50.0 [47.7,53.1] 48.5 [47.7,52.6] 0.45
Median MLA, mm2 3.80 [3.10,4.76] 3.86 [3.08,4.87] 3.98 [3.26,5.17] 0.44
≥1 TCFA 52.4% 50.6% 51.6% 0.78
≥1 TCFA with MLA ≤ 4.0 mm2 and plaque burden ≥70% 13.7% 18.9% 12.9% 0.21
NCL-MACE at 1 year 1.9% 6.2% 3.4% 0.06
NCL-MACE at 2 years 4.3% 9.4% 13.9% 0.02
NCL-MACE at 3 years 6.8% 11.7% 21.1% 0.01
TCFA=thin cap fibroatheroma; MLA=minimal lumen area; NCL=non-culprit lesion; MACE=major adverse cardiovascular events
